image
Healthcare - Medical - Care Facilities - NASDAQ - US
$ 0.0361
-4.75 %
$ 688 K
Market Cap
-0.03
P/E
1. INTRINSIC VALUE

Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary health care related products and services. It operates through two segments, Healthcare Services, and Product Manufacturing and Development. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services. It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics, including pediatric, adult, and geriatric populations.[ Read More ]

The intrinsic value of one NVOS stock under the base case scenario is HIDDEN Compared to the current market price of 0.0361 USD, Novo Integrated Sciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVOS

image
FINANCIALS
12.6 M REVENUE
7.11%
-8.55 M OPERATING INCOME
65.82%
-13.3 M NET INCOME
59.84%
-2.24 M OPERATING CASH FLOW
61.88%
-49.2 K INVESTING CASH FLOW
-30.11%
764 K FINANCING CASH FLOW
278.84%
3.15 M REVENUE
-0.59%
-2.52 M OPERATING INCOME
-63.67%
-13.7 M NET INCOME
-400.51%
-658 K OPERATING CASH FLOW
61.60%
-2 K INVESTING CASH FLOW
0.00%
1.82 M FINANCING CASH FLOW
57066.35%
Balance Sheet Decomposition Novo Integrated Sciences, Inc.
image
Current Assets 4.39 M
Cash & Short-Term Investments 416 K
Receivables 1.47 M
Other Current Assets 2.5 M
Non-Current Assets 31.2 M
Long-Term Investments 0
PP&E 7.37 M
Other Non-Current Assets 23.8 M
Current Liabilities 7.9 M
Accounts Payable 3.51 M
Short-Term Debt 2.71 M
Other Current Liabilities 1.68 M
Non-Current Liabilities 3.16 M
Long-Term Debt 1.76 M
Other Non-Current Liabilities 1.4 M
EFFICIENCY
Earnings Waterfall Novo Integrated Sciences, Inc.
image
Revenue 12.6 M
Cost Of Revenue 7.62 M
Gross Profit 4.95 M
Operating Expenses 13.5 M
Operating Income -8.55 M
Other Expenses 4.72 M
Net Income -13.3 M
RATIOS
39.39% GROSS MARGIN
39.39%
-68.03% OPERATING MARGIN
-68.03%
-105.11% NET MARGIN
-105.11%
-53.25% ROE
-53.25%
-37.16% ROA
-37.16%
-31.48% ROIC
-31.48%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Novo Integrated Sciences, Inc.
image
Net Income -13.3 M
Depreciation & Amortization 2.3 M
Capital Expenditures -49.2 K
Stock-Based Compensation 385 K
Change in Working Capital 461 K
Others 7.42 M
Free Cash Flow -2.29 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Novo Integrated Sciences, Inc.
image
NVOS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Novo Integrated Sciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 years ago
Apr 19, 2022
Bought 675 USD
Oliva Robert Letterio
director:
+ 300
2.25 USD
3 years ago
Apr 21, 2021
Bought 27.6 K USD
Oliva Robert Letterio
Director
+ 13000
2.12 USD
3 years ago
Feb 23, 2021
Bought 890 USD
Oliva Robert Letterio
Director
+ 200
4.45 USD
3 years ago
Feb 22, 2021
Bought 40.3 K USD
Oliva Robert Letterio
Director
+ 9355
4.31 USD
17 years ago
Nov 01, 2007
Sell 8.75 K USD
Alpha Engines, Corp.
10 percent owner
- 6000
1.4584 USD
17 years ago
Nov 05, 2007
Sell 6.25 K USD
Alpha Engines, Corp.
10 percent owner
- 5000
1.25 USD
17 years ago
Nov 06, 2007
Sell 910 USD
Alpha Engines, Corp.
10 percent owner
- 700
1.3 USD
17 years ago
Nov 12, 2007
Sell 3.32 K USD
Alpha Engines, Corp.
10 percent owner
- 5000
0.6632 USD
17 years ago
Nov 12, 2007
Sell 2.85 K USD
Alpha Engines, Corp.
10 percent owner
- 4000
0.7113 USD
17 years ago
Oct 29, 2007
Sell 27.5 K USD
Alpha Engines, Corp.
10 percent owner
- 20000
1.374 USD
17 years ago
Oct 30, 2007
Sell 7.03 K USD
Alpha Engines, Corp.
10 percent owner
- 5000
1.406 USD
17 years ago
Oct 23, 2007
Sell 14 K USD
Alpha Engines, Corp.
10 percent owner
- 10000
1.4 USD
17 years ago
Oct 23, 2007
Sell 13.5 K USD
ROUSE MICHAEL
Chairman & CEO
- 10000
1.349 USD
17 years ago
Oct 24, 2007
Sell 13.7 K USD
ROUSE MICHAEL
Chairman & CEO
- 9500
1.44 USD
17 years ago
Jan 26, 2007
Sell 13.6 K USD
Alpha Engines, Corp.
10 percent owner
- 20000
0.68 USD
17 years ago
Jan 26, 2007
Sell 6.69 K USD
Alpha Engines, Corp.
10 percent owner
- 12500
0.535 USD
17 years ago
Jan 29, 2007
Sell 8.85 K USD
Alpha Engines, Corp.
10 percent owner
- 17345
0.51 USD
17 years ago
Jan 30, 2007
Sell 7.5 K USD
Alpha Engines, Corp.
10 percent owner
- 16310
0.46 USD
17 years ago
Jan 31, 2007
Sell 4.5 K USD
Alpha Engines, Corp.
10 percent owner
- 10000
0.45 USD
17 years ago
Dec 18, 2006
Bought 1.7 K USD
ROUSE MICHAEL
Chairman & CEO
+ 2833
0.6 USD
18 years ago
Nov 03, 2006
Sell 710 USD
ROUSE MICHAEL
Chairman & CEO
- 1000
0.71 USD
18 years ago
Oct 31, 2006
Sell 1.06 K USD
ROUSE MICHAEL
Chairman & CEO
- 1500
0.71 USD
18 years ago
Oct 03, 2006
Bought 6.1 B USD
Alpha Engines, Corp.
10 percent owner
+ 100000
61000 USD
18 years ago
Jul 14, 2006
Bought 166 M USD
Alpha Engines, Corp.
10 percent owner
+ 13958
11864.76 USD
18 years ago
Aug 14, 2006
Bought 10.5 B USD
ROUSE MICHAEL
Chairman & CEO
+ 111295
94601.51 USD
18 years ago
Jun 21, 2006
Sell 9.44 K USD
Alpha Engines, Corp.
10 percent owner
- 6600
1.43 USD
18 years ago
Jun 19, 2006
Sell 12.2 K USD
ROUSE MICHAEL
Chairman & CEO
- 10000
1.22 USD
18 years ago
Jun 21, 2006
Sell 1.57 K USD
ROUSE MICHAEL
Chairman & CEO
- 1000
1.57 USD
18 years ago
May 12, 2006
Sell 1.68 K USD
ROUSE MICHAEL
Chairman & CEO
- 1000
1.68 USD
18 years ago
May 17, 2006
Sell 4.73 K USD
Alpha Engines, Corp.
10 percent owner
- 4300
1.1 USD
18 years ago
May 12, 2006
Sell 1.7 K USD
ROUSE MICHAEL
Chairman & CEO
- 1000
1.7 USD
18 years ago
May 08, 2006
Sell 14.4 K USD
ROUSE MICHAEL
Chairman & CEO
- 10000
1.44 USD
18 years ago
May 09, 2006
Sell 3.36 K USD
ROUSE MICHAEL
Chairman & CEO
- 2000
1.68 USD
18 years ago
May 03, 2006
Sell 2.4 K USD
ROUSE MICHAEL
Chairman & CEO
- 2000
1.2 USD
18 years ago
May 04, 2006
Sell 3.6 K USD
ROUSE MICHAEL
Chairman & CEO
- 3000
1.2 USD
18 years ago
May 05, 2006
Bought 720 USD
ROUSE MICHAEL
Chairman & CEO
+ 500
1.44 USD
18 years ago
May 05, 2006
Sell 2.6 K USD
ROUSE MICHAEL
Chairman & CEO
- 2000
1.3 USD
18 years ago
Apr 28, 2006
Sell 2.53 K USD
ROUSE MICHAEL
Chairman & CEO
- 2300
1.1 USD
18 years ago
Apr 28, 2006
Sell 1.44 K USD
ROUSE MICHAEL
Chairman & CEO
- 1200
1.2 USD
18 years ago
May 01, 2006
Sell 10.3 K USD
ROUSE MICHAEL
Chairman & CEO
- 10000
1.03 USD
18 years ago
Apr 25, 2006
Sell 178 USD
ROUSE MICHAEL
Chairman & CEO
- 100
1.78 USD
18 years ago
Apr 26, 2006
Sell 20.5 K USD
ROUSE MICHAEL
Chairman & CEO
- 19500
1.05 USD
18 years ago
Apr 26, 2006
Sell 720 USD
ROUSE MICHAEL
Chairman & CEO
- 500
1.44 USD
18 years ago
Apr 26, 2006
Sell 720 USD
ROUSE MICHAEL
Chairman & CEO
- 500
1.44 USD
18 years ago
Apr 27, 2006
Sell 30.4 K USD
ROUSE MICHAEL
Chairman & CEO
- 29000
1.05 USD
18 years ago
Apr 27, 2006
Sell 720 USD
ROUSE MICHAEL
Chairman & CEO
- 500
1.44 USD
7. News
Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results. businesswire.com - 3 months ago
What's Going On With Novo Integrated Sciences Stock On Friday? On Friday, Novo Integrated Sciences Inc NVOS announced it received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (SBLC). benzinga.com - 3 months ago
Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program. businesswire.com - 4 months ago
Novo Integrated Sciences: A Coil Spring Ready To Explode Novo Integrated Sciences is a unique nano-cap company with the potential for massive growth through game-changing, non-dilutive financing. Novo is working towards closing 3 major funding transactions, including a $70M promissory note, $78M for the monetization of gemstones expected to deliver surplus cash, and a one-billion-dollar gold-backed bond. Success in securing funding will be a true inflection point for NVOS, dramatically changing the fortunes of the company for the better. seekingalpha.com - 4 months ago
Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received confirmation of the issuance of a Standby Letter of Credit (“SBLC”) by HSBC for delivery by Swift MT760, as part of a program designed for monetizing SBLCs. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SB. businesswire.com - 5 months ago
Novo Integrated Sciences' Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the Company's Board of Directors has approved an increase of up to $10 million maximum amount, from the previously announced up to $5 million maximum amount, for the repurchase of the Company's outstanding common stock from time to time in the open market at prevailing market prices or in privately negotiated transactions. The increased maximum amount available for purchase. businesswire.com - 5 months ago
Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that its wholly owned Canadian subsidiary, Acenzia Inc. (“Acenzia”), has been selected by Protein Industries Canada to participate in a new project to bring new protein products with a superior nutritional amino acid profile to the global marketplace. The total project is expected to see approximately $5.4 million invested into the development, reformulation, and commerciali. businesswire.com - 5 months ago
Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today the Company and RC Consulting Consortium Group LLC, in favor of SCP Tourbillion Monaco (“RC”), have amended the prepayment terms and conditions of the previously disclosed $70,000,000 promissory note, dated April 26, 2023 (the “RC Note”) to provide that, at any time after 12 months and no later than 60 months from the commencement of the term of the RC Note and prior to an e. businesswire.com - 5 months ago
KBRA Assigns AA- to Pennsylvania Turnpike Commission Turnpike Revenue Bonds, Series C of 2024; Affirms Related Ratings NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns a long-term rating of AA- to the Pennsylvania Turnpike Commission Turnpike Revenue Bonds, Series C of 2024. KBRA additionally affirms: The long-term rating of AA- for the Commission's outstanding Turnpike Revenue Bonds The long-term rating of A+ for the Commission's outstanding Turnpike Subordinate Revenue Bonds The long-term rating of AA- for the Commission's outstanding Motor License Fund-Enhanced Turnpike Subordinate Special Revenue Bonds The Outlook f. businesswire.com - 5 months ago
Why Is Novo Integrated Sciences (NVOS) Stock Up 139% Today? Novo Integrated Sciences (NASDAQ: NVOS ) stock is rocketing higher on Friday after the company said it wants to further maximize its stock repurchase program. Novo Integrated Sciences' Board of Directors is weighing options for a potential increase to the company's stock repurchase program. investorplace.com - 5 months ago
Novo Integrated Sciences' Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences' Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program. businesswire.com - 5 months ago
Novo Integrated Sciences Receives Confirmation of Ready, Willing and Able (RWA) Issued by HSBC for SBLC Leasing and Monetizing Program BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Receives Confirmation of Ready, Willing and Able (RWA) Issued by HSBC for SBLC Leasing and Monetizing Program. businesswire.com - 5 months ago
8. Profile Summary

Novo Integrated Sciences, Inc. NVOS

image
COUNTRY US
INDUSTRY Medical - Care Facilities
MARKET CAP $ 688 K
Dividend Yield 0.00%
Description Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary health care related products and services. It operates through two segments, Healthcare Services, and Product Manufacturing and Development. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services. It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics, including pediatric, adult, and geriatric populations. In addition, the company offers eldercare physiotherapy services, such as long-term care homes, retirement homes, community based home care physiotherapy, community based group exercise classes and fall prevention programs, and community-based outpatient clinics; and elderly occupational therapy services for retirement home and community, and long-term care sectors. Further, it offers medical technology services, such as telemedicine and remote patient monitoring; and develops and distributes personalized health and wellness product solutions. The company operates 16 owned clinics. The company was incorporated in 2000 and is based in Bellevue, Washington. Novo Integrated Sciences, Inc. operates as a subsidiary of ALMC-ASAP Holdings, Inc.
Contact 11120 NE 2nd Street, Bellevue, WA, 98004 https://novointegrated.com
IPO Date Feb. 23, 2021
Employees 127
Officers Mr. Robert Mattacchione Chairman of the Board & Chief Executive Officer Mr. Christopher Mehlin David Chief Operating Officer & Director